Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3939 - Soluble PD-L1 as a prognostic factor in advanced acral and mucosal melanoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Pathology/Molecular Biology

Tumour Site

Melanoma

Presenters

Xuan Wang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

X. Wang1, C. Cui2, J. Yu1, Y. Kong2, L. Si2, Z. Chi3, X. Sheng4, L. Mao4, B. Lian2, B. Tang2, X. Yan3, J. Guo4

Author affiliations

  • 1 Renal Cancer And Melanoma, Beijing Cancer Hospital, 100141 - Beijing/CN
  • 2 Renal Cancer And Melanoma, Beijing Cancer Hospital, 100142 - Beijing/CN
  • 3 Renal Cancer And Melanoma, Beijing Cancer Hospital, Beijing/CN
  • 4 Renal Cancer And Melanoma, Beijing Cancer Hospital, 100000 - Beijing/CN
More

Resources

Abstract 3939

Background

Elevated levels of soluble PD-L1 (sPD-L1) have been associated with worse prognosis in renal cell carcinoma and multiple myeloma. However, the regulatory roles and function of sPD-L1 in advanced melanoma are not fully understood. This study was designed to evaluate the association between circulating sPD-L1 expression and prognosis in patients with advanced acral and mucosal melanoma.

Methods

Totally 102 untreated advanced acral and mucosal melanoma patients from Peking University Cancer Hospital between Jan 2012 and Dec 2015 were enrolled in the present study. Peripheral blood samples were obtained from 40 healthy donors as control. Circulating sPD-L1 expression was tested by enzymelinked immunosorbent assay (ELISA).

Results

The advanced melanoma cohort includes 58 acral melanoma and 44 mucosal melanoma. Concentrations of sPD-L1 (2.91ng/mL) were elevated in the plasma of prior to treatment advanced melanoma patients in comparison with healthy donors (0.59ng/mL). The expression of sPD-L1 in serum was found to be highly up-regulated in 39 (38.2%) of 102 cases. The sPD-L1 concentration appeared to be significantly related with subtype (arcal 3.14 vs. mucosal 2.60 ng/mL P = 0.004). No significant association was observed between serum sPD-L1 level and other clinicopathological variables as: BRAF mutation, LDH level, tumor burden and peripheral blood CD4+/CD8+. There were no associations between sPD-L1 and chemotherapy clinical responses in our cohort. But the overall survival rates were statistically estimated with the expression of sPD-L1. The OS in this cohort with high and low up-regulated sPD-L1 expression levels was 8.50 months and 11.64 months, respectively (p = 0.022).

Conclusions

sPD-L1 was elevated in advance acral and mucosal melanoma patients and may play an important role in patients prognosis.

Clinical trial identification

Legal entity responsible for the study

Peking University Cancer Hospital & Research Institute.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.